Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, Kasiske BL, Deswal A, deFilippi CR, Cleland JGF, Anker SD, Herzog CA, Cheung M, Wheeler DC, Winkelmayer WC, McCullough PA; Conference Participants.

Kidney Int. 2019 Jun;95(6):1304-1317. doi: 10.1016/j.kint.2019.02.022. Epub 2019 Apr 30.

PMID:
31053387
2.

Untargeted metabolomics reveals N, N, N-trimethyl-L-alanyl-L-proline betaine (TMAP) as a novel biomarker of kidney function.

Velenosi TJ, Thomson BKA, Tonial NC, RaoPeters AAE, Mio MA, Lajoie GA, Garg AX, House AA, Urquhart BL.

Sci Rep. 2019 May 2;9(1):6831. doi: 10.1038/s41598-019-42992-3.

3.

Arterial Stiffness in the Heart Disease of CKD.

Zanoli L, Lentini P, Briet M, Castellino P, House AA, London GM, Malatino L, McCullough PA, Mikhailidis DP, Boutouyrie P.

J Am Soc Nephrol. 2019 Jun;30(6):918-928. doi: 10.1681/ASN.2019020117. Epub 2019 Apr 30.

PMID:
31040188
4.

Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch.

Xu Q, House AA, Leckie S, Gunaratnam L, Luke PP, Jevnikar AM.

Hum Immunol. 2019 Mar 20. pii: S0198-8859(18)31099-1. doi: 10.1016/j.humimm.2019.03.015. [Epub ahead of print]

PMID:
30904438
5.

Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.

Weiner DE, Park M, Tighiouart H, Joseph AA, Carpenter MA, Goyal N, House AA, Hsu CY, Ix JH, Jacques PF, Kew CE, Kim SJ, Kusek JW, Pesavento TE, Pfeffer MA, Smith SR, Weir MR, Levey AS, Bostom AG.

Am J Kidney Dis. 2019 Jan;73(1):51-61. doi: 10.1053/j.ajkd.2018.05.015. Epub 2018 Jul 20.

PMID:
30037726
6.

Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: The CKD WIT Randomized Clinical Trial.

Clark WF, Sontrop JM, Huang SH, Gallo K, Moist L, House AA, Cuerden MS, Weir MA, Bagga A, Brimble S, Burke A, Muirhead N, Pandeya S, Garg AX.

JAMA. 2018 May 8;319(18):1870-1879. doi: 10.1001/jama.2018.4930.

PMID:
29801012
7.

Management of Heart Failure in Advancing CKD: Core Curriculum 2018.

House AA.

Am J Kidney Dis. 2018 Aug;72(2):284-295. doi: 10.1053/j.ajkd.2017.12.006. Epub 2018 Feb 23.

PMID:
29478868
8.

Hemodialysis Infection Prevention Protocols Ontario-Shower Technique (HIPPO-ST): A Pilot Randomized Trial.

Kosa SD, Gafni A, House AA, Lawrence J, Moist L, Nathoo B, Tam P, Sarabia A, Thabane L, Wu G, Lok CE.

Kidney Int Rep. 2016 Nov 8;2(2):228-238. doi: 10.1016/j.ekir.2016.11.001. eCollection 2017 Mar.

9.

The Chronic Kidney Disease Water Intake Trial: Protocol of a Randomized Controlled Trial.

Clark WF, Huang SH, Garg AX, Gallo K, House AA, Moist L, Weir MA, Sontrop JM.

Can J Kidney Health Dis. 2017 Aug 22;4:2054358117725106. doi: 10.1177/2054358117725106. eCollection 2017.

10.

Characteristics and Outcomes of Patients Discharged Home from an Emergency Department with AKI.

Acedillo RR, Wald R, McArthur E, Nash DM, Silver SA, James MT, Schull MJ, Siew ED, Matheny ME, House AA, Garg AX.

Clin J Am Soc Nephrol. 2017 Jul 20. pii: CJN.10431016. doi: 10.2215/CJN.10431016. [Epub ahead of print]

11.

CRRTnet: a prospective, multi-national, observational study of continuous renal replacement therapy practices.

Heung M, Bagshaw SM, House AA, Juncos LA, Piazza R, Goldstein SL.

BMC Nephrol. 2017 Jul 6;18(1):222. doi: 10.1186/s12882-017-0650-2.

12.

Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort.

Merhi B, Shireman T, Carpenter MA, Kusek JW, Jacques P, Pfeffer M, Rao M, Foster MC, Kim SJ, Pesavento TE, Smith SR, Kew CE, House AA, Gohh R, Weiner DE, Levey AS, Ix JH, Bostom A.

Am J Kidney Dis. 2017 Sep;70(3):377-385. doi: 10.1053/j.ajkd.2017.04.014. Epub 2017 Jun 2.

13.

The Risk of Acute Rejection Following Kidney Transplant by 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Status: A Prospective Cohort Study.

Zimmerman D, House AA, Kim SJ, Booth RA, Zhang T, Ramsay T, Knoll G.

Can J Kidney Health Dis. 2017 Apr 10;4:2054358117699822. doi: 10.1177/2054358117699822. eCollection 2017.

14.

Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.

Hosseini-Moghaddam SM, Alhomayeed B, Soliman N, Weir MA, House AA.

Transpl Infect Dis. 2016 Jun;18(3):423-30. doi: 10.1111/tid.12533. Epub 2016 May 23.

PMID:
27016725
15.

Drug Disposition Issues in CKD: Implications for Drug Discovery and Regulatory Approval.

Tieu A, House AA, Urquhart BL.

Adv Chronic Kidney Dis. 2016 Mar;23(2):63-6. doi: 10.1053/j.ackd.2016.01.013. Review.

PMID:
26979144
16.

Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial.

Sontrop JM, Huang SH, Garg AX, Moist L, House AA, Gallo K, Clark WF.

BMJ Open. 2015 Nov 24;5(11):e008634. doi: 10.1136/bmjopen-2015-008634.

17.

Intimate partner violence.

House AA.

CMAJ. 2015 Nov 17;187(17):1312. doi: 10.1503/cmaj.1150071. No abstract available.

18.

Folic Acid for Stroke Prevention: Time to Revisit Vitamin Therapy in Patients With Kidney Disease?

House AA, Urquhart BL.

Am J Kidney Dis. 2015 Dec;66(6):942-4. doi: 10.1053/j.ajkd.2015.06.009. Epub 2015 Jul 14. No abstract available.

PMID:
26187470
19.

Association between muscle hydration measures acquired using bioelectrical impedance spectroscopy and magnetic resonance imaging in healthy and hemodialysis population.

Sawant A, House AA, Chesworth BM, Connelly DM, Lindsay R, Gati J, Bartha R, Overend TJ.

Physiol Rep. 2015 Jan 27;3(1). pii: e12219. doi: 10.14814/phy2.12219. Print 2015 Jan 1.

20.

The (99m)Tc-DTPA urinary clearance method may be preferable to the plasma disappearance method for assessing glomerular filtration rate in diabetic nephropathy.

Huang SH, Eliasziw M, Spence JD, Filler G, Vezina WC, Churchill DN, Cattran DC, Richardson B, House AA.

Nephron Clin Pract. 2014;128(3-4):367-72. doi: 10.1159/000368901. Epub 2015 Jan 8.

PMID:
25571980
21.

Enzymatic and non-enzymatic mechanisms of dimesna metabolism.

Cutler MJ, Velenosi TJ, Bodalia A, House AA, Urquhart BL, Freeman DJ.

Amino Acids. 2015 Mar;47(3):511-23. doi: 10.1007/s00726-014-1882-0. Epub 2014 Dec 10.

PMID:
25488427
22.

Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.

Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, House AA, Urquhart BL.

Am J Kidney Dis. 2015 Apr;65(4):574-82. doi: 10.1053/j.ajkd.2014.09.015. Epub 2014 Nov 21.

PMID:
25453994
23.

Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial.

Knoll GA, Humar A, Fergusson D, Johnston O, House AA, Kim SJ, Ramsay T, Chassé M, Pang X, Zaltzman J, Cockfield S, Cantarovich M, Karpinski M, Lebel L, Gill JS.

JAMA. 2014 Nov 26;312(20):2106-14. doi: 10.1001/jama.2014.14721.

PMID:
25399012
24.

Anabolic Effect of Exercise Training in People with End-Stage Renal Disease on Hemodialysis: A Systematic Review with Meta-analysis.

Sawant A, House AA, Overend TJ.

Physiother Can. 2014 Winter;66(1):44-53. doi: 10.3138/ptc.2012-59.

25.

Preoperative Cylex assay predicts rejection risk in patients with kidney transplant.

Myslik F, House AA, Yanko D, Warren J, Caumartin Y, Rehman F, Jevnikar AM, Stitt L, Luke PP.

Clin Transplant. 2014 May;28(5):606-10. doi: 10.1111/ctr.12359. Epub 2014 Apr 21.

PMID:
24628326
26.

The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial.

Clark WF, Sontrop JM, Huang SH, Gallo K, Moist L, House AA, Weir MA, Garg AX.

BMJ Open. 2013 Dec 20;3(12):e003666. doi: 10.1136/bmjopen-2013-003666.

27.

Cardiorenal syndrome: introduction.

House AA.

Clin J Am Soc Nephrol. 2013 Oct;8(10):1798-9. doi: 10.2215/CJN.06030613. No abstract available.

28.

Cardiorenal syndrome: new developments in the understanding and pharmacologic management.

House AA.

Clin J Am Soc Nephrol. 2013 Oct;8(10):1808-15. doi: 10.2215/CJN.02920313. Epub 2013 Aug 8. Review.

29.

Plasma sodium setpoint: is it constant or changed by hemodialysis prescription?

Thomson BK, Huang SH, Chan CT, House AA, Lindsay RM.

ASAIO J. 2013 Sep-Oct;59(5):497-504. doi: 10.1097/MAT.0b013e31829ed829.

PMID:
23896770
30.

Quinolone prophylaxis for the prevention of BK virus infection in kidney transplantation: study protocol for a randomized controlled trial.

Humar A, Gill J, Johnston O, Fergusson D, House AA, Lebel L, Cockfield S, Kim SJ, Zaltzman J, Cantarovich M, Karpinski M, Ramsay T, Knoll GA.

Trials. 2013 Jun 21;14:185. doi: 10.1186/1745-6215-14-185.

31.

Progression of carotid plaque volume predicts cardiovascular events.

Wannarong T, Parraga G, Buchanan D, Fenster A, House AA, Hackam DG, Spence JD.

Stroke. 2013 Jul;44(7):1859-65. doi: 10.1161/STROKEAHA.113.001461. Epub 2013 Jun 4.

PMID:
23735956
32.

Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI).

Cruz DN, Schmidt-Ott KM, Vescovo G, House AA, Kellum JA, Ronco C, McCullough PA.

Contrib Nephrol. 2013;182:117-36. doi: 10.1159/000349968. Epub 2013 May 13.

33.

Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI).

McCullough PA, Kellum JA, Haase M, Müller C, Damman K, Murray PT, Cruz D, House AA, Schmidt-Ott KM, Vescovo G, Bagshaw SM, Hoste EA, Briguori C, Braam B, Chawla LS, Costanzo MR, Tumlin JA, Herzog CA, Mehta RL, Rabb H, Shaw AD, Singbartl K, Ronco C.

Contrib Nephrol. 2013;182:82-98. doi: 10.1159/000349966. Epub 2013 May 13.

PMID:
23689657
34.

Five-year experience with donation after cardiac death kidney transplantation in a Canadian transplant program: Factors affecting outcomes.

Moser M, Sharpe M, Weernink C, Brown H, McGregor T, House AA, Luke PP.

Can Urol Assoc J. 2012 Dec;6(6):448-52. doi: 10.5489/cuaj.12104.

35.

Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI)--a pilot randomized controlled trial of hemofiltration versus hemodialysis: a Canadian Critical Care Trials Group project.

Wald R, Friedrich JO, Bagshaw SM, Burns KE, Garg AX, Hladunewich MA, House AA, Lapinsky S, Klein D, Pannu NI, Pope K, Richardson RM, Thorpe K, Adhikari NK.

Crit Care. 2012 Oct 24;16(5):R205. doi: 10.1186/cc11835.

36.

Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study.

Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW.

Clin Transplant. 2012 Jul-Aug;26(4):E438-46. doi: 10.1111/j.1399-0012.2012.01676.x. Epub 2012 Jul 9.

37.

Timing the initiation of renal replacement therapy for acute kidney injury in Canadian intensive care units: a multicentre observational study.

Clark E, Wald R, Levin A, Bouchard J, Adhikari NK, Hladunewich M, Richardson RM, James MT, Walsh MW, House AA, Moist L, Stollery DE, Burns KE, Friedrich JO, Barton J, Lafrance JP, Pannu N, Bagshaw SM; Canadian Acute Kidney Injury (CANAKI) Investigators.

Can J Anaesth. 2012 Sep;59(9):861-70. doi: 10.1007/s12630-012-9750-4. Epub 2012 Jun 30.

PMID:
22752716
38.

Morphological, electrophysiological, and metabolic characteristics of skeletal muscle in people with end-stage renal disease: a critical review.

Sawant A, Garland SJ, House AA, Overend TJ.

Physiother Can. 2011 Summer;63(3):355-76. doi: 10.3138/ptc.2010-18. Epub 2011 Aug 10. Review.

39.

Bioelectrical impedance analysis in the assessment of hydration status in peritoneal dialysis patients.

Haapio M, Lentini P, House AA, de Cal M, Cruz DN, Gong D, Rodighiero MP, Dell'Aquila R, Ronco C.

Contrib Nephrol. 2012;178:238-45. doi: 10.1159/000337885. Epub 2012 May 25.

PMID:
22652744
40.

Cardio-renal syndrome type 4: epidemiology, pathophysiology and treatment.

House AA.

Semin Nephrol. 2012 Jan;32(1):40-8. doi: 10.1016/j.semnephrol.2011.11.006. Review.

PMID:
22365161
41.
42.

Sulodexide for diabetic nephropathy: another one bites the dust.

House AA, Weir MA.

Am J Kidney Dis. 2011 Nov;58(5):692-4. doi: 10.1053/j.ajkd.2011.08.011. No abstract available.

PMID:
22014634
43.

Total pelvic exenteration for rectal cancer: outcomes and prognostic factors.

Domes TS, Colquhoun PH, Taylor B, Izawa JI, House AA, Luke PP, Izawa JI.

Can J Surg. 2011 Dec;54(6):387-93. doi: 10.1503/cjs.014010.

44.

Are there any contraindications to using midodrine for intradialytic hypotension?

House AA.

Semin Dial. 2011 Jul-Aug;24(4):402-3. doi: 10.1111/j.1525-139X.2011.00902.x. Epub 2011 Jul 29. No abstract available.

PMID:
21801220
45.

Clinical factors associated with initiation of renal replacement therapy in critically ill patients with acute kidney injury-a prospective multicenter observational study.

Bagshaw SM, Wald R, Barton J, Burns KE, Friedrich JO, House AA, James MT, Levin A, Moist L, Pannu N, Stollery DE, Walsh MW.

J Crit Care. 2012 Jun;27(3):268-75. doi: 10.1016/j.jcrc.2011.06.003. Epub 2011 Jul 27.

PMID:
21798709
46.

B-type natriuretic Peptide in the critically ill with acute kidney injury.

de Cal M, Haapio M, Cruz DN, Lentini P, House AA, Bobek I, Virzì GM, Corradi V, Basso F, Piccinni P, D'Angelo A, Chang JW, Rosner MH, Ronco C.

Int J Nephrol. 2011;2011:951629. doi: 10.4061/2011/951629. Epub 2011 Jun 22.

47.

Pharmacological management of cardiorenal syndromes.

House AA, Haapio M, Lassus J, Bellomo R, Ronco C.

Int J Nephrol. 2011;2011:630809. doi: 10.4061/2011/630809. Epub 2011 May 26.

48.

The burden of cardiovascular risk in chronic kidney disease and dialysis patients (cardiorenal syndrome type 4).

House AA, Ronco C.

Contrib Nephrol. 2011;171:50-6. doi: 10.1159/000327175. Epub 2011 May 23. Review.

PMID:
21625089
49.

Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.

Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M.

Circulation. 2011 Apr 26;123(16):1763-70. doi: 10.1161/CIRCULATIONAHA.110.000588. Epub 2011 Apr 11.

50.

Body mass index and the risk of progression of chronic kidney disease.

Khedr A, Khedr E, House AA.

J Ren Nutr. 2011 Nov;21(6):455-61. doi: 10.1053/j.jrn.2010.12.001. Epub 2011 Mar 31.

PMID:
21454093

Supplemental Content

Loading ...
Support Center